The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) was down 1.92 percent over the last five trading days and ended the week at 3,086.24 points. The Index is up 11.28 percent year-to-date.
Last week President Donald Trump presented his new budget which would see an increase in the FDA’s medical product user fees. Alexion announced significant layoffs and a shift in the strategy of the company. The XBI is just above $70 and IBB is just under $300. MedGadget reported in WIRED’s health conference in 2017 with various industry leaders discussing what’s next in medical treatment.
- Cerulean Pharma (NASDAQ:CERU)
- Catalyst Pharmaceutical (NASDAQ:CPRX)
- Neovasc Inc. (NASDAQ:NVCN)
- Arbutus Biopharma Corp (NASDAQ:ABUS)
- Tetraphase Pharmaceuticals (NASDAQ:TTPH)
This company is creating a nanoparticle-drug conjugate to fight tumor cells in cancer. Cerulean recently announced a review to evaluate potentials moves like a sale, merger or a strategic investment.
Cerulean Pharma gained 118.42 percent over the five-day trading week and ended at $3.32 per share.
This biopharmaceutical is focused on developing and commercializing innovative therapies for treating rare diseases. The company recently announced positive test results for a treatment of a rare neuromuscular disease, with no current treatment.
Catalyst Pharmaceutical gained 38.74 percent over the five-day trading week and ended at $1.54 per share.
Neovasc is a medical device company for products in the cardiovascular marketplace. They will host their upcoming fourth quarter and fiscal year 2016 conference call on March 23. However, there has been no further recent news from the company to explain last week’s rise in share price.
Neovasc gained 34.09 percent over the five-day trading week and ended at $1.77 per share.
Arbutus is a biopharmaceutical looking for a cure to treat patients with chronic hepatitis B infection. The company announced last week it licensed its proprietary lipid nanoparticle technology with Alexion Pharmaceuticals (NASDAQ:ALXN). Alexion will pay Arbutus $7.5 million upfront
Arbutus Biopharma gained 25.93 percent over the five-day trading week and ended at $3.40 per share.
This clinical stage life science company is researching a way to address antibiotic resistance. Tetraphase recently reported its financial results for its fourth quarter and 2016. However, there has been no further recent news from the company to explain last week’s rise in share price.
Tetraphase Pharmaceuticals gained 19.14 percent over the five-day trading week and ended at $8.28 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Related reading, previous gainers: